EC OKs Xeplion for Treatment of Schizophrenia

The EC has approved Janssen-Cilag’s XEPLION (paliperidone palmitate) for the treatment of schizophrenia.

Janssen-Cilag International NV announced that XEPLION (paliperidone palmitate), a once monthly, long-acting injectable, antipsychotic, has received approval from the European Commission for the treatment of schizophrenia.

Schizophrenia is relatively common and the prevalence is similar around the world. Schizophrenia is a devastating mental illness for both the patients and their families and friends, as it seriously impairs a person's ability to think clearly, relate to others and to function properly in society.

Patients with schizophrenia who are non-adherent to medication are up to five times more likely to r